Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Dec 2024: Trial registered, NCT06734130
  2. 10 Jan 2025: Trial started, NCT06734130

The trials

NCT06734130: Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

State
Under way
Phase
Phase 2
People
25 taking part
Started
10 Jan 2025
Primary completion
Jan 2029
Arms
Adaptive Androgen Deprivation and Docetaxel Treatment
Results
None posted
  1. 16 Dec 2024: Trial registered
  2. 10 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.